The Clinical Trials Centre of the Macau University of Science and Technology (MUST-CTC) has achieved a significant milestone. On 13th November 2026, Global biopharmaceutical leader Boehringer Ingelheim (BI) resented the centre with the "2026 BI PI Award — Innovation Pioneer Award" in recognition of MUST-CTC’s successful coordination in achieving the First Patient In (FPI) in Macao for two international, multi-centre clinical trials. Chair Professor Paul, Kwong-Hang Tam, Vice-President of MUST and Chief Director of MUST-CTC, accepted the award on behalf of the centre.
The two recognised studies include Macao's first novel drug clinical trial, FIBRONEER™-SARD (targeting Interstitial Lung Disease Associated with Systemic Autoimmune Rheumatic Diseases), and Macao's second novel drug clinical trial, EASi-PROTKT™ (targeting Type 2 Diabetes Mellitus patients with hypertension and cardiovascular disease). Both trials are sponsored by BI, MUST-CTC is responsible for the daily coordination and execution of the trial activities. The University Hospital (UH) serves as the clinical research site, and the University of Hong Kong Clinical Trials Centre (HKU-CTC) provides strategic coordination and platform support.
Attending the award ceremony from BI were Ms. Ying Zhang, TA Head of Inflammation, Clinical Development Operations, T.C.M.; Ms. Angela Xiao, TA Head of Cardiovascular-Renal-Metabolic, Clinical Development Operations, T.C.M.; Mr. Jiayi Ma and Ms. Jun Huang, Clinical Trial Manager, Clinical Development Operations. MUST Representatives include Chair Professor Paul, Kwong-Hang Tam, Vice-President of MUST and Chief Director of MUST-CTC; Dr. Valencia Chang, Executive Director of MUST-CTC, Vice President and Administrative Director of UH; Professor Brian Tomlinson, Principal Investigator of the two clinical trial projects; along with team members.
This recognition highlights MUST-CTC’s capability to conduct high-standard international clinical trials for novel drugs. Looking ahead, MUST-CTC will continue to collaborate closely with leading global pharmaceutical companies as well as partners in Hong Kong and Macao to bring more high-level clinical research projects to Macao.
Award Ceremony
Chair Professor Paul, Kwong-Hang Tam, Vice-President of MUST and Chief Director of MUST-CTC (Left), accepted the award on behalf of the centre from Ms. Ying Zhang, TA Head of Inflammation, Clinical Development Operations, T.C.M of BI (Right)
2026 BI PI Award — Innovation Pioneer Award
Group Photo
